Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 5/20 | 0.42 |
| ▸ | ABL1 | P00519 | 8/20 | 0.39 |
| ▸ | BCR | P11274 | 8/20 | 0.39 |
| ▸ | SGK1 | O00141 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4798614 | 0.84 | PDPK1 (0.47) | JAK2MKNK1MKNK2PDPK1ABL1 | |
| SCHEMBL3168792 | 0.84 | JAK2 (0.50) | JAK2MKNK1MKNK2PDPK1ABL1 | |
| SCHEMBL3173793 | 0.83 | JAK2 (0.46) | JAK2MKNK1MKNK2PDPK1ABL1 | |
| SCHEMBL4147254 | 0.83 | JAK2 (0.40) | JAK2MKNK1MKNK2PDPK1ABL1 | |
| SCHEMBL3174551 | 0.82 | PDPK1 (0.46) | JAK2MKNK1MKNK2PDPK1ABL1 | |
| SCHEMBL3175009 | 0.81 | JAK2 (0.44) | JAK2MKNK1MKNK2PDPK1ABL1 | |
| SCHEMBL4800934 | 0.80 | JAK2 (0.44) | JAK2MKNK1MKNK2PDPK1ABL1 | |
| SCHEMBL3168954 | 0.80 | ABL1 (0.45) | JAK2MKNK1MKNK2PDPK1ABL1 | |
| SCHEMBL3166844 | 0.78 | KDR (0.42) | JAK2MKNK1MKNK2PDPK1 | |
| SCHEMBL3172972 | 0.78 | CHEK1 (0.43) | JAK2MKNK1MKNK2PDPK1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466295-B2 | Thiophene derivatives as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-06-18 | — | — | US | claimed |
| US-20090253766-A1 | THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | claimed |
| US-8466295-B2 | Thiophene derivatives as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-06-18 | — | — | US | disclosed |
| US-20090253766-A1 | THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| WO-2007070816-A2 | THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253766-A1 | THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS | TFPI, F12, F11 | JAK2 641/4885MKNK1 1432/4885MKNK2 1572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.